ranolazine

04/27/2010 - "Ranolazine was associated with a significant reduction in recurrent ischemia in women (13.0% versus 18.2%; hazard ratio, 0.71; 95% confidence interval, 0.57 to 0.88; P=0.002). "
12/01/2006 - "One trial demonstrated that monotherapy with extended-release ranolazine was effective against angina and ischemia in patients with CSA. "
07/01/2008 - "For patients whose ischemia cannot be optimally controlled with traditional anti-ischemic agents, a novel antianginal and anti-ischemic agent (ie, ranolazine) has promise in reducing refractory ischemia as add-on therapy. "
12/01/2006 - "Ranolazine (9 microM) reduced d[Ca2+]i accumulation during ischemia as well as reperfusion and improved recovery of LV function. "
01/31/2012 - "Additionally, future research is warranted to study the effect of newer medical therapies such as ranolazine or selected use of revascularization (for example, guided by fractional flow reserve) in those patients with persistent silent ischemia despite optimal current-era medical therapy."

09/01/2012 - "A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation. "
01/01/2014 - "Refractory atrial fibrillation effectively treated with ranolazine."
10/01/2014 - "Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications."
04/03/2010 - "Ranolazine, another atrial-selective agent initially developed as an antianginal, has efficacy for atrial fibrillation and is being tested in prospective clinical trials. "
01/01/2014 - "Efficacy of ranolazine for rhythm control in an elderly patient with paroxysmal atrial fibrillation."

10/24/2013 - "Ranolazine is effective in myocardial ischemia therapy]."
11/15/2012 - "Ranolazine ameliorates myocardial ischemia by augmenting myocardial blood flow; likely by a reduction in the extravascular compression of small vessels. "
05/01/2011 - "We previously reported that ranolazine improved myocardial ischemia during exercise myocardial perfusion imaging (MPI). "
01/01/2011 - "Ranolazine also inhibits triggered activity in animal studies and has anti-arrhythmic properties in patients with ischemic heart disease. "
07/01/2008 - "Three randomized, clinical trials of the drug ranolazine relate to patients with symptomatic myocardial ischemia. "

04/20/2001 - "Ranolazine caused a significant reduction in myocardial infarct size of approximately 33% compared to saline control (P<0.05). "
12/01/2006 - "Ongoing studies will address whether ranolazine can reduce clinical end points such as cardiovascular death and myocardial infarction."
10/01/2014 - "Ranolazine treatment for myocardial infarction? "
09/01/2014 - "The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats."
07/01/2006 - "Ranolazine reduces angina, but there is little information on its effects in acute myocardial infarction. "

12/01/2013 - "Ranolazine improved the CCS angina class and reduced hospitalizations over a 12-month follow-up period in a group of patients with difficult-to-treat refractory angina pectoris."
12/01/2013 - "There are only limited data concerning the efficacy of ranolazine in reducing healthcare resource utilization in patients with refractory angina pectoris. "
07/01/2007 - "Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris."
01/01/2015 - "Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study."
03/15/2014 - "The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials."